



# sensei<sup>TM</sup> BIO

## **Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference**

March 6, 2023

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at Oppenheimer's 33<sup>rd</sup> Annual Healthcare Conference. The presentation will be available at 8:00 a.m. ET on Monday, March 13<sup>th</sup>, 2023.

A webcast of Sensei's presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available [here](#).

### **About Sensei Biotherapeutics**

Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb<sup>TM</sup> (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei's lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit [www.senseibio.com](http://www.senseibio.com), and follow the company on Twitter @SenseiBio and [LinkedIn](#).

### **Investor Contact:**

Michael Biega  
Senior Director, Investor Relations  
Sensei Biotherapeutics  
[mbiega@senseibio.com](mailto:mbiega@senseibio.com)

### **Media Contact:**

Chris Railey  
Ten Bridge Communications  
[chris@tenbridgecommunications.com](mailto:chris@tenbridgecommunications.com)